Patients with cancer may use botanical dietary supplements (BDS) in an attempt to manage the side effects of chemotherapy, yet evidence about BDS use among patients with cancer is limited. The authors examined trends in BDS use among US adults according to cancer status and patient characteristics. METHODS: A serial, cross-sectional study was conducted using data from the National Health and Nutrition Examination Survey from 1999 through 2014 (n 5 43,644). Self-reported cancer diagnosis history and any BDS use in the preceding 30 days were determined. The prevalence of BDS use was calculated in each cycle for respondents with and without cancer, both overall and by patient characteristics. Simple linear regression models were applied to test for trends in BDS use at a 2-sided P value < .05. Multiple logistic regression models were performed to identify the patient factors associated with BDS use. The results were weighted to represent national estimates. RESULTS: The prevalence of BDS use was greater among participants who had cancer compared with participants who did not have cancer, but trends remained stable during 1999 through 2014 for both groups. Trends in BDS use declined in patients with cancer who were older (P trend 5 .047), had a low annual family income (P trend 5 .028), and had a lower education level (P trend 5 .004). Among the respondents without cancer, trends in BDS use declined in those who were middle-aged (P trend 5 .025), non-Hispanic whites (P trend 5 .025), those with a lower education level (P trend 5 .011), and those who were not receiving prescription medication (P trend 5 .036). Patient age, sex, race/ethnicity, income, education, and health conditions were associated with BDS use. CONCLUSIONS: The overall use of BDS remained stable during 1999 through 2014 for US adults with and without cancer, but it varied by individual characteristics. Cancer 2018;124:1207-15. V C 2017 American Cancer Society.
INTRODUCTION
Cancer was the second leading cause of death in the United States in 2013, 1 representing nearly 8 million individuals who were newly diagnosed between 2001 and 2011. 2 Although the overall 5-year relative survival rate has been improved by 20.3% since 1975 for all cancer types, 3 with more potent and aggressive treatments and with the advent of cancer precision medicine, patients with cancer are often faced with managing side effects of their cancer therapy. Patients may seek additional alternative therapies, such as complementary and alternative medicine (CAM), in an attempt to improve general health. 4 Approximately 75% to 90% of patients with colorectal, prostate, and pediatric cancer reportedly use CAMs, 5 of which the most popular are herb supplements and vitamins, also called botanical dietary supplements (BDS).
effects of chemotherapy, slowing progression of cancer, and improving quality of life. [9] [10] [11] The concomitant use of anticancer drugs and BDS, however, could lead to serious safety issues, causing pharmacokinetic and pharmacodynamic interactions in individuals with cancer. 6 Although more evidence in chemotherapy-BDS interaction studies is needed, 6 ,10-17 a first step is to understand the patterns of BDS use among patients with cancer.
By using National Health and Nutrition Examination Survey (NHANES) data from 1999 to 2014, we examined trends in BDS use among US adults with and without cancer, overall and by patient demographic characteristics, socioeconomic factors, the number of prescription medications, and other health conditions. In addition, patient factors associated with any BDS use also were identified.
MATERIALS AND METHODS

Study Population
This was a serial, cross-sectional study using 8 cycles of the NHANES data (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) . Nationally representative, noninstitutionalized civilians living in the United States who completed the continuous 2-year-cycle NHANES household interviews were included. The overall unweighted response rate for the entire 8 cycles was 78%, and the cycle-specific, unweighted response rate ranged from 71% to 84%. 18 The study population was limited to adults (aged 20 years). Self-reported cancer status (yes/no) was determined by the survey question, "Have you/has sample person ever been told by a physician or other health professional that you/she/he had cancer or a malignancy of any kind?" from questionnaire data in the Medical Conditions file. Respondents who had missing or incomplete selfreported data on cancer status or education level were excluded. The final study sample included 4023 adults with cancer (weighted; n 5 19,283,697) and 39,621 adults without cancer (weighted; n 5 192,560,731). This study was approved by the Auburn University Institutional Review Board.
Botanical Dietary Supplement Use
We used the NHANES DS data to code respondent's BDS use as "yes" if they answered "yes" to the question asking whether they used any DSs in the prior 30 days, and also coded their receipt of BDS by calculating the variable DSDCNTB 1 (the number of botanicals in supplements). Otherwise, their BDS use was coded as "no." The BDS use identified in this study included both singleingredient and combination BDS products.
Covariates
To identify factors associated with any BDS use, the following patient factors were assessed using questionnaire data from the Prescription Medications and Medical Conditions files and demographic data from the Demographic Variables and Sample Weights file: anticancer medication treatment, demographic and socioeconomic characteristics, number of prescription medications, and other health conditions. An anticancer medication treatment variable (yes/no) was defined for participants with cancer from the Prescription Medications file as "yes" if respondents reported receiving any prescription medications (including National Cancer Institute-published drugs approved for cancer, 19 approved for conditions related to cancer, and off-label use in cancer treatment) in the past 30 days. Patient demographic characteristics included age (ages 20-34, 35-64, 65 years), sex (male, female), and race/ethnicity (non-Hispanic white, other races). Socioeconomic factors included marital status (married, never married, widowed or divorced, unknown), employment status (unemployed/unknown, employed), annual family income status based on the Federal Poverty Level (FPL) (<100% FPL, 100%-200% FPL, 200%-400% FPL, >400% FPL, unknown), education level (high school or lower, some college, bachelor or higher), and health insurance status (yes/no). In addition, the self-reported number of unique prescription medications and other health conditions (in total, 26 other health conditions excluding cancer) also were identified.
Statistical Analyses
Trends in the prevalence of any BDS use were estimated overall and by participant demographic and socioeconomic characteristics and the number of prescription medications among participants with and without cancer, respectively. Simple linear regression models with a count-independent variable for temporal cycle (cycles 1-8) were used to test (2-sided) for trends across 8 cycles. To compare the difference of any BDS use between participants with and without cancer, generalized linear models with the generalized linear model (GENMOD) procedure, binomial distribution, and log-link function were used to calculate the marginal mean difference (MMD) in the prevalence of BDS use within each NHANES cycle, both overall and by participant factors.
To identify the factors associated with BDS use in participants with and without cancer, in total, 43,644 individuals were derived from the 8-cycle data for bivariate and multivariate analyses. The bivariate analyses (chisquare tests) compared proportions of any BDS use between by participant characteristics among patients with and without cancer, respectively. Multiple logistic regression models were used to identify factors associated with any BDS use in both groups. All analyses were weighted and were conducted using the SAS statistical software package (version 9.4; SAS Institute, Inc, Cary, NC). Statistical significance was set at P < .05.
RESULTS
Results From Trend Analyses
Overall, there was no statistically significant change in the prevalence of any BDS use among patients with versus without cancer during 1999 through 2014 (P trend 5 .129 and .068, respectively) ( Fig. 1) . The prevalence of BDS use was greater among patients with cancer (range, 15.5%-23.6%) than among respondents without cancer (range, 12.3%-18.0%) in each NHANES cycle. The MMDs in BDS use between US adults with and without cancer in each cycle were significant, ranging from 1.1% to 5.9% (Supporting Fig. 1 ; see online supporting information). However, the trend in MMDs did not indicate statistical significance (P trend 5 .68) (Supporting Fig. 1 ; see online supporting information).
In addition, trends in BDS use remained stable in most patient subgroups among patients with cancer ( Fig. 2) . However, trends decreased significantly in patients with cancer aged 65 years (P trend 5 .047), those with a high school or lower education (P trend 5 .004), and those with a low annual family income (<100% FPL; P trend 5 .028). Among respondents without cancer (Fig. 3) , trends in any BDS use declined significantly in middle-aged adults (P trend 5 .025), non-Hispanic whites (P trend 5 .025), those with a high school or lower education level (P trend 5 .011) and those with no prescription medication use (P trend 5 .036). Trends in MMDs of BDS use between patients with and without cancer by patient factors also remained stable (Supporting Fig. 2 ; see online supporting information).
Results in Factors Associated With Any BDS Use
From 1999 through 2014, in total, 18.8% of US adults with cancer and 15.6% of US respondents without cancer reported using any BDS in the preceding 30 days (Table  1) . Among those with cancer, bivariate results demonstrated that patients who were non-Hispanic white, employed, had higher family income and education levels, and received fewer prescription medications were more likely to use any BDS compared with their counterparts (all P < .05) ( Table 1 ). In the multivariate analysis adjusting for all covariates, race/ethnicity (non-Hispanic white) and higher family income and education levels were identified as independent factors associated with any BDS use among patients with cancer ( Table 2 ). Among the respondents without cancer, results from the bivariate analysis indicated that individuals who were older, female, non-Hispanic white, married, employed, had higher family income and education levels, had health insurance, received fewer prescription medications, and had from 2 to 4 other health conditions were more likely to use any BDS compared with their counterparts (all P < .05) ( Table 1 ). In the multivariate analysis, older age, sex (female), race/ethnicity (non-Hispanic white), and higher family income and education levels remained as independent factors associated with any BDS use ( Table 2) .
DISCUSSION
This study is among the first to examine and compare the trends in any BDS use in a population-based sample of nationally representative US adults with and without cancer, overall and by patient factors. From 1999 to 2014, the overall prevalence of any BDS use among adults with and without cancer remained stable. The prevalence of any BDS use among those with cancer was higher than that among those without cancer: Approximately 1 in 5 adults with cancer reported using BDS compared with approximately 1 in 7 adults without cancer. Indeed, some studies have indicated that BDS may be used to reduce the side effects of chemotherapy and symptom burdens, slow the progression of cancer, and improve quality of life. 9, 10, 20 Our finding of a greater prevalence of BDS use among patients with versus without cancer is in line with that previous evidence.
Despite stable trends in the overall use of any BDS, some variances in BDS use among adults with and without cancer were observed. Specifically, there was a decrease in BDS use among patients with cancer aged 65 years, those with a high school or lower education, and those with lower income. It is noteworthy that increased trends in any DS use among older adults in the United States were observed in previous studies. 21, 22 However, those studies examined trends in any DS use, whereas the current study was focused on BDS, which is a subset of DSs. In previous studies, 21, 22 a dominant increase in the use of DSs like omega-3 fish oils and vitamin D could explain the overall increased trends in supplement use among older US adults, especially considering the increased reports supporting possible cognitive benefits in older adults for conditions like cardiovascular disease. 23, 24 According to American Institute for Cancer Research nutritional guidelines, 25 DSs are not recommended for daily use and cancer prevention for patients with cancer, which may be 1 reason for the decreased trend in BDS use observed among older patients with cancer in the current study. The decreased trends in BDS use observed in patients who have cancer with lower education and income levels may be related to affordability and access to health care services. Among the adults without cancer, decreased trends in BDS use were observed among participants who were ages 35 to 64 years, and were non-Hispanic whites, had a high school or lower education, and were not receiving any prescription medications. These findings are consistent with evidence in the patterns of all DSs among the general US population. 21 Other studies using data from the National Health Interview Surveys also identified significant drops in the rate of herbal and supplement use between 2002 and 2012 among younger adults (ages 18-64 years) and those with lower educational levels. 26, 27 In addition, the current study identified specific patient factors associated with BDS use among US adults with and without cancer. Similar to the previous study of DS use among US adults from 1999 to 2012, 21 we observed that the respondents without cancer who were older, female, and non-Hispanic white were more likely to use any BDS. However, among the patients with cancer, age and sex were not significantly associated with BDS use, which was not consistent with some previous studies, which demonstrated that, among patients with cancer, younger individuals [28] [29] [30] or women 28, 30, 31 were more likely to use CAM or DSs. Although those previous studies focused on the use of CAM and DSs among patients with cancer or studied only patients who had only 1 type of cancer, such as colorectal cancer 28 or breast cancer 29 ; in the current study, we quantified BDS use among nationally representative patients with any type of cancer. In addition, our finding of an association between higher levels of education and income with a greater likelihood of BDS use in adults with and without cancer is consistent with the increased use of CAM and DSs observed in previous studies. [31] [32] [33] [34] [35] For example, to identify factors associated with the selection of alternative medicine, Johnson et al recently reported that US patients with cancer in their alternative medicine group were more likely to have less comorbidities, higher stage disease, and higher levels of income and education according to data from the National Cancer Database between 2004 and 2013. 35 Indeed, patients with cancer who have higher socioeconomic factors may be more likely to afford and purchase BDS, even considering their cancer therapies and the out-of-pocket costs for BDS. 36, 37 It is also worth noting that, in the current study, anticancer treatment was not associated with BDS use among patients with cancer. In addition, patients who had cancer and were receiving 7 prescription medications were less likely to use any BDS compared with those without any prescription medication use. One possible explanation is that patients with cancer who receive more prescription medications have a decreased desire to add supplements, or at least a decreased desire to add those that are not critically necessary, because they may have a higher chance of experiencing botanical-medication interactions, which could affect the metabolism, excretion, or therapeutic efficacy of medication treatments [12] [13] [14] and even may cause serious safety issues. 6, 10 For example, for patients with hormone-sensitive cancers, such as prostate or breast cancers, it is recommended to avoid taking soy, a common botanical phytoestrogen, because it may interfere with the inhibitory effect of anticancer therapies on tumor growth. [38] [39] [40] In addition, there are some concerns regarding the quality, toxicity, contamination, standardization, purity, and stability of BDS over time and under various storage circumstances, such as high heat, illumination, or humidity. 36 However, according to a national survey, greater than 60% of people using CAM in the general US population never informed their physicians. 41 A systematic review study also reported that from 31% to 68% of US patients with cancer who were using DSs did not tell their physicians. 42 In addition, 14 US-based companies were brought to light on April 25, 2017, when the US Food and Drug Administration posted warning letters because these companies were illegally selling more than 65 products, including various DSs that fraudulently claim to prevent, treat, or cure cancer without any proof. 43 Given the high prevalence of BDS use among patients with cancer, it is critical to encourage patient-provider communication about BDS use and to monitor BDS use and its potential interaction with cancer therapies.
The current study has several limitations. First, it had a cross-sectional design, which means we could examine only associations instead of causality. Second, the study population did not include institutionalized US individuals or individuals aged <20 years; therefore, the findings may not be applied to those excluded populations. Third, during the NHANES in-home survey, only BDS and anticancer prescription medication use in the past 30 days was recorded, which likely has underestimated their use over a longer recall period. Fourth, most of the variables were self-reported from the NHANES data, which could introduce self-report and recall biases. Fifth, because of the constraints of a small sample size among patients with cancer, we only estimated overall BDS use, but it is possible that BDS use could vary by individual types of BDS, which could be investigated further in future studies with larger samples. Last but not least, in the current study, we could not address concerns related to the stability of BDS ingredients or interactions between BDS use and cancer therapy because of a lack of such data in the NHANES.
In conclusion, this study fills important knowledge gaps of BDS use among US adults. The overall use of BDS remained stable from 1999 to 2014 among individuals with and without cancer. However, BDS use varied by patient characteristics. Given the high prevalence of BDS use among patients with cancer, it is critical to monitor BDS use and its potential interaction with cancer therapies. Future research on chemotherapy-BDS interactions and adverse events is warranted.
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